Resection of initially unresectable hepatocellular carcinoma with atezolizumab plus bevacizumab Additional study: Identification of biomarkers for predicting therapeutic effects and adverse events - RACB additional study

ational Center for Global Health and Medicine0 sites50 target enrollmentJanuary 15, 2022

Overview

Phase: 未知
Intervention: Not specified
Conditions: Not specified
Sponsor: ational Center for Global Health and Medicine
Enrollment: 50
Status: Not yet recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

January 15, 2022

End Date

March 31, 2026

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

ational Center for Global Health and Medicine

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•1\. Currently receiving oral or parenteral anticoagulants or thrombolytics within 10 days prior to enrollment. 2\. Have untreated or not adequately treated esophageal varices at high risk of bleeding, or a history of bleeding due to esophageal varices within 180 days prior to enrollment. 3\. Had thrombosis and/or embolism within 180 days before enrollment. 4\. Has undergone major surgical procedures within 28 days before enrollment. 5\. Has received systemic immunostimulatory agents within 180 days prior to enrollment. 6\. Has received systemic immunosuppressants within 14 days before enrollment. 7\.History and complications of autoimmune disease within 180 days prior to enrollment 8\. History of active double cancer or malignancy. 9\. Currently participating in another study of unapproved drugs or a study requiring intervention. 10\.Critical cardiovascular disease, unstable arrhythmia or unstable angina in the 90 days prior to enrollment. 11\.Pregnant, breastfeeding, positive in pregnancy test, women and men unwilling to contraceptive during the study period. 12\. Has clinically uncontrolled pleural effusion, pericardial effusion or ascites. 13\. Has complications of hepatic encephalopathy 14\. Uncontrollable hypertension, severe infection, hemodialysis 15\. Has a history of serious allergic or anaphylactic reactions to chimeric antibody, humanized antibody, or fusion protein. 16\.Hypersensitivity to either Chinese hamster ovary cell\-derived products or components of atezolizumab or bevacizumab products. 17\.Has a history of hemorrhagic disease, gastrointestinal hemorrhage or active hemoptysis. 18\. Difficult to ingest medication 19\.HIV\-positive 20\. Active pulmonary fibrosis or interstitial pneumonia 21\.Has received blood transfusions or G\-CSF products within 14 days prior to enrollment 22\. The attending physician judges that the patient is not suitable for participating in the study.